Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab plus radiofrequency ablation for unresectable uveal melanoma liver metastases
NL-OMON41385Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in intraocular melanoma, melanoma, sponsored by Netherlands Cancer Institute. Started May 2012; status: recruiting.
02
Drugs
ipilimumab
03
Conditions
intraocular melanomamelanoma
Beyond the preview
Go deeper on NL-OMON41385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41385.